OQROGet OQRO Pro
Insider trade

Boston Scientific (BSX)CEO sold ~$14.9M

Michael F Mahoney, CEO at Boston Scientific, sold ~$14.9M of Boston Scientific shares.

~$14.9M
Approx. value · 160K sh @ $93.49
1.41M
Holds after · shares reported
Traded
Feb 2, 2026
Filed
Feb 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 18, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  2. Dec 16, 2025Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  3. Dec 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  4. Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  5. Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
  6. Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  7. Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  8. Feb 2, 2026 · this disclosureInsiderCEO sold ~$14.9M of BSX shares in the open market

What came next

  1. Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  2. Feb 2, 2026InsiderCEO sold ~$113K of BSX shares in the open market
  3. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  4. Feb 10, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  5. Feb 12, 2026Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  6. Feb 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of…”
  7. Feb 26, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
  8. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: In re: Boston Scientific Corporation Securities Litigation
  9. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: Troike v. Boston Scientific Corporation
  10. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  11. Apr 22, 2026Company filing · Form 8-K · ResultsReported its results
  12. Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  13. Apr 30, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
  14. May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 5.1%
  15. May 12, 2026FDARecall: Orca Single Use Air/Water and Suction Valves, Material Number (UPN) SUV-617-50; The Orca Air/Water Valve is intended to be used to control the air/water functi…
  16. May 15, 2026FDAFDA device clearance: TruSelect™ 2.6 Microcatheter
  17. May 18, 2026FDAFDA device clearance: MOSES Raydar™
  18. May 19, 2026Insider · First insider buy since Dec 2024Director purchased ~$125K of BSX shares in the open market
  19. May 20, 2026Insider · 3 peopleInsiders: 3 purchases (~$429K)
  20. May 21, 2026FDARecall: CRE Wireguided 10-12mm 240cm
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

Other recent filings by Michael F Mahoney, Chairman, President & CEO

The full history of Michael F Mahoney, Chairman, President & CEO is on the profile page.

How this filing works

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data